Physician profile
John Tarbox
NPI 1609359652
$12,097.26
in general payments reported to CMS, 2019-2025
45 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,219 · 2022: $2,321 · 2023: $3,072 · 2024: $1,942 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,557.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,989.40 | 2021-2025 | |
| Novo Nordisk INC | $2,347.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,090.36 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $935.86 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $480.86 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $356.52 | 2022-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $351.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $192.63 | 2023-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.46 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $180.54 | 2025 | |
| Sunovion Pharmaceuticals INC. | $176.10 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.28 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $137.44 | 2024 | Xarelto |
| Viiv Healthcare Company | $134.05 | 2021-2024 | Dovato |
| Corcept Therapeutics | $116.86 | 2023 | Korlym |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $108.20 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Phathom Pharmaceuticals, INC. | $103.87 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $101.71 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $98.77 | 2023-2025 | |
| Verona Pharma, INC. | $91.14 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $59.94 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alkermes, INC. | $59.67 | 2023 | Aristada, Lybalvi |
| Corium, LLC | $55.29 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $54.44 | 2023 | |
| Axsome Therapeutics, INC. | $52.72 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $44.88 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $43.46 | 2022-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.66 | 2021-2023 | Relistor |
| Otsuka America Pharmaceutical, INC. | $38.52 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.25 | 2022 | |
| Optinose US, INC. | $35.15 | 2021 | |
| Lundbeck LLC | $31.34 | 2024-2025 | Rexulti |
| Dexcom, INC. | $21.33 | 2024 | Dexcom G6 Transmitter |
| Halozyme INC | $19.56 | 2023 | |
| Dynavax Technologies Corporation | $18.72 | 2023 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2023 | Trintellix |
| Collegium Pharmaceutical, INC. | $18.37 | 2023 | Xtampza |
| Emd Serono, INC. | $18.03 | 2024 | |
| Xeris Pharmaceuticals, INC. | $16.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.21 | 2021 | |
| Indivior INC. | $15.60 | 2023 | Sublocade |
| Impel Pharmaceuticals INC. | $14.78 | 2023 | Trudhesa |
| Ibsa Pharma INC. | $14.62 | 2025 | Licart, Tirosint, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $13.88 | 2024 | |
| Tolmar, INC. | $13.78 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tarbox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.